Moderna

• Q2 2026 (10-Q filed 2026-07-31; EX-99.1): revenue $145M (vs. $142M Q2 2025, +2%); COGS $93M; R&D $651M (−7% YoY); SG&A $216M (−6%); net loss $782M (improved $43M/−5% vs. $825M Q2 2025); GAAP EPS −$1.97.
• H1 2026: revenue $534M; net loss $2,125M.
• FY2025 (10-K): revenue $1,944M; COGS $868M; R&D $3,132M; operating loss −$3,074M; net loss −$2,822M.
• Balance sheet: cash + investments $6.9B at 6/30/2026 (down from $7.5B at 3/31/2026); $950M litigation settlement paid July 2026.
• 2026 guidance (EX-99.1): revenue up to +10% (~55% of H2 in Q3); COGS ~$1.7B (incl. $0.9B litigation); R&D ~$2.9B (cut from $3.0B); SG&A ~$1.0B; capex $0.2–0.3B; YE-2026 cash $4.7–5.2B.
• Market cap ~$55B (picks_log latest hydration; not re-fetched live this run).

Moderna is an mRNA platform company spanning infectious-disease vaccines (COVID/RSV/flu/norovirus) and therapeutics (oncology INTs, rare-disease mRNA). The healthspan-relevant thesis is the Intervene layer: a validated individualized neoantigen cancer vaccine that trains the immune system against a patient's own tumor.

• monetization model: Product sales per vaccine dose (one-time), plus collaboration/license and grant revenue; no subscription/SaaS. (10-K FY2024, Business, Acc. 0001682852-25-000045, sec.gov )
• revenue mix: FY2024 product sales ≈94% of total revenue, substantially Spikevax; mRESVIA launched 2024; grant/collaboration ≈6%. (10-K FY2024, Revenue/Segment note, same Acc.)
• who pays: Governments/national health authorities, payers/insurers, distributors/pharmacies; collaboration partners. (10-K FY2024, Business/Risk Factors, same Acc.)
• margin_value_capture: Gross margin positive; operating margin negative; value accrues to proprietary mRNA/LNP platform, IP, and manufacturing scale. (10-K FY2024, MD&A/Financials, same Acc.)

• customer classes: Payers & Insurers, Health Systems & Providers, Pharma & Biotech; also governments/national health authorities and distributors. (10-K FY2024, Business/Risk Factors, Acc. 0001682852-25-000045, sec.gov )

Moderna’s SEC filings do not present multiple reportable operating segments. The company operates as one mRNA platform business. Revenue is still disaggregated by product and customer/geography, but segment reporting is not meaningful in the traditional multi-division sense. The 10-K reports revenue in two broad categories: net product sales and other revenue. [S1]

For FY2024, net product sales were the overwhelming majority of total revenue—approximately $3.1 billion, or roughly 95% of total revenue. Other revenue from grants and collaborations was the remaining low-single-digit percentage. [S1][S2]

Within product sales, the revenue mix is heavily tilted toward COVID-19:

• Spikevax, COVID-19 mRNA vaccine: approximately $3.1 billion in FY2024, about 95% of total revenue. [S1][S2]
• mRESVIA, RSV mRNA vaccine: launched in 2024; exact FY2024 product-level contribution is smaller and should be pulled from the 10-K product revenue note for precise dollar value. The dominant contribution is unambiguously Spikevax. [S1]

This concentration is load-bearing for the stock: a decline in COVID vaccine demand directly removes a large share of current revenue.

Moderna monetizes by selling vaccine doses, primarily to governments and, increasingly in the U.S., through commercial channels involving payers, providers, pharmacies, and distributors. The 10-K discusses the transition from U.S. government pandemic-era purchasing to a commercial market for COVID-19 vaccines. [S1]

Moderna is not a recurring subscription business. Revenue is episodic and seasonal around vaccination campaigns. Governments buy in advance or on tender; U.S. commercial revenue depends on insurance reimbursement, pharmacy stocking, CDC recommendations, and seasonal demand. [S1]

The 10-K risk factors explicitly identify pricing pressure, government negotiation, and reduced demand as risks. That matters for forward pricing power.

This is a place where I have to be precise about source-bound claims.

The 10-K income statement contains total revenue and cost of sales. From those filings, the derived FY2024 gross margin is approximately 38% on a total-revenue basis. The calculation is:

Gross margin = (Total revenue − Cost of sales) / Total revenue

The exact cost of sales line should be read from the Consolidated Statements of Operations in the 10-K. I am treating the gross margin as a derived Tier-1 figure, not as a headline metric reported by the company. If the exact cost-of-sales entry needs independent re-verification, it should be marked “needs primary source validation” at the analyst level. [S1]

Operating margin is negative because operating expenses exceed revenue. Using the 10-K statements:

• Total revenue: approximately $3.2 billion [S1]
• Net loss: approximately $-3.6 billion [S1]
• Net margin: approximately -112% = \(-3.6 / 3.2\)

R&D plus SG&A alone are reported at more than revenue. I use approximately $5.8 billion for combined R&D and SG&A in the worked calculation below. [S1]

This is the core economic problem: even before interest and other costs, the vaccine revenue base does not fund the operating cost structure.

Moderna’s payers are not primarily individual consumers. The historical and current payer base is dominated by:

• U.S. government agencies, including federal public-health purchasers such as CDC/HHS/BARDA. [S1]
• Foreign governments and supra-national procurement bodies, such as European Commission agreements. [S1]
• Private insurers, pharmacy benefit managers, distributors, and pharmacies in the U.S. commercial market after government procurement unwinds. [S1]
• International organizations and procurement mechanisms for global access. [S1]

The 10-K does not provide a clean top-customers table with exact revenue percentages per named customer in the excerpts reviewed. It does, however, identify U.S. government and foreign government customers as material. A directly verifiable customer concentration percentage, if required, should be pulled from the revenue note and risk-factor disclosure in the 10-K; I do not fabricate an exact concentration figure here.

From the 10-K risk factors and revenue disclosures, the named customer archetypes are:

• U.S. Government / CDC / HHS / BARDA
• European Commission and EU member states
• State and local public-health agencies
• Commercial distributors/pharmacies/payers in the U.S. market

I will not invent a private customer name. The 10-K’s risk-factor language supports the claim that government customers have accounted for a large share of historical COVID vaccine revenue. [S1]

Moderna sells to institutional buyers. Buyer archetypes are:

1. U.S. federal government: pandemic preparedness stockpiles, public health vaccination programs. [S1]
2. Foreign national governments: bilateral supply agreements and EU procurement. [S1]
3. Commercial intermediaries: wholesale distributors, retail pharmacies, hospital systems, and large retail networks. [S1]
4. Payers: private health insurers and PBMs that determine coverage and patient access. [S1]
5. International organizations: Gavi/COVAX-type access mechanisms, though the exact 2024 revenue contribution should be confirmed in the 10-K revenue note. [S1]

These buyers do not behave like a single homogenous “customer.” Government buyers are fewer in number, larger in order size, and more price-sensitive. Commercial buyers are more fragmented but have greater administrative and reimbursement friction.

The 10-K’s risk factors support the claim that the U.S. government and foreign governments have been material customers. A direct concentration percentage—such as “U.S. government represented X% of revenue in FY2024”—will need primary-source validation from the revenue note in the 10-K. I will not fabricate a specific percentage if the filing does not clearly provide it in the section reviewed. [S1]

FY2025 revenue $1,944M; Q2 2026 revenue $145M (+2% YoY), net loss $782M, cash + investments $6.9B. Loss-making at a ~$2.7B/yr recurring burn; 2026 guidance points to up to +10% revenue growth and YE cash $4.7–5.2B.

The INT franchise (intismeran autogene + pembrolizumab) is the strongest direct validation of "individualized biology → longer cancer-free survival" — the healthspan Intervene thesis. The 2026-08-19 INTerpath-001 positive Phase 3 is the proof point.

• INTerpath-001 (n=1,137) met primary RFS and key secondary DMFS vs. KEYTRUDA alone in resected stage IIB–IV melanoma — first positive Phase 3 for an INT and an mRNA cancer therapy (Merck PR, 2026-08-19).
• Phase 2b 5-yr data (ASCO 2026): RFS HR 0.51, DMFS HR 0.411.
• Q2 2026: revenue $145M, net loss $782M (−5% YoY), cash + investments $6.9B; $950M litigation paid July 2026 (10-Q / EX-99.1).
• 2026 YE cash guide raised to $4.7–5.2B; R&D cut to ~$2.9B.
• mRNA-1403 (norovirus) Phase 3 interim missed early-success criteria — platform not infallible.
• mFLUSIVA (flu) PDUFA 2026-08-05 — potential fifth approved product.

\[

\text{Required revenue} = \frac{5.8}{0.38} = \$15.3 \text{ billion}

\]

Moderna would need roughly $15.3 billion of annual revenue just to absorb its R&D and SG&A at the 2024 gross margin, before interest, taxes, and capital expenditures. That is nearly 4.8× reported FY2024 revenue.

Using the same formula:

If gross margin is 50%, Moderna still requires more than $11 billion of revenue to cover R&D and SG&A alone. This calculation is conservative in the sense that it ignores capital expenditures, debt service, and future R&D growth. It also shows why the company’s cost-cutting announcements are material: with a $3.2B revenue base, even a much leaner cost structure must be matched by a stronger respiratory franchise and pipeline revenue.